Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.58 |
| ▸ | ADH1B | P00325 | 1/20 | 0.57 |
| ▸ | ADH1C | P00326 | 1/20 | 0.57 |
| ▸ | ADH1A | P07327 | 1/20 | 0.57 |
| ▸ | ADH4 | P08319 | 1/20 | 0.57 |
| ▸ | ADH7 | P40394 | 1/20 | 0.57 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6385119 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL29136407 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL29136406 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL28708092 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL6395851 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL6390459 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL7093599 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL126229 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL4456628 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| Bromide SCHEMBL27860834 | 1.00 | TSHR (0.87) | TSHRALDH1A1EPHX1ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1087 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865585-B1 | BIOCHIP AND MANUFACTURING METHOD THEREFOR | GENEMIND BIOSCIENCES CO LTD (CN) | 2026-05-27 | — | — | EP | claimed |
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | WILLIAM M YARBROUGH FOUND (US) | 2026-02-26 | — | — | US | claimed |
| EP-4604928-A1 | LYMPHATIC ENDOTHELIAL CELL-SPECIFIC LIPID NANOPARTICLE AND USES THEREOF | Georgia Tech Research Corporation (US) | 2025-08-27 | — | — | EP | claimed |
| US-12310939-B2 | Method for treating rheumatoid arthritis | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-05-27 | — | — | US | claimed |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | THE WILLIAM M YARBROUGH FOUND (US) | 2025-05-22 | — | — | US | claimed |
| CN-113913944-B | Protein co-modified DNA chip and preparation method thereof | 深圳市真迈生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-12239626-B2 | Method for treating infectious diseases with isothiocyanate functional compounds | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-03-04 | — | — | US | claimed |
| US-12178795-B2 | Method for treating metastatic prostate cancer | THE WILLIAM YARBROUGH FOUNDATION (US) | 2024-12-31 | — | — | US | claimed |
| WO-2024086810-A1 | LYMPHATIC ENDOTHELIAL CELL-SPECIFIC LIPID NANOPARTICLE AND USES THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2024-04-25 | — | — | WO | claimed |
| CN-117843603-A | Ionizable lipid material and application thereof in preparation of nucleic acid delivery carrier | 华中科技大学 | 2024-04-09 | — | — | CN | claimed |
| US-20100285099-A1 | VACCINATION BY TRANSCUTANEOUS TARGETING | FONDATION BETTENCOURT-SCHUELLER (FR) | 2010-11-11 | — | — | US | claimed |
| WO-2009101412-A1 | TOPICAL PHARMACEUTICAL COMPOSITION | CIPLA LIMITED (IN) | 2009-08-20 | — | — | WO | claimed |
| EP-1970440-A1 | Polymerase stabilization by ionic detergents | Qiagen GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| EP-1898949-A1 | VACCINATION BY TRANSCUTANEOUS TARGETING | Fondation Bettencourt-Schueller (FR) | 2008-03-19 | — | — | EP | claimed |
| WO-2006136959-A1 | VACCINATION BY TRANSCUTANEOUS TARGETING | FONDATION BETTENCOURT-SCHUELLER (FR) | 2006-12-28 | — | — | WO | claimed |
| CN-1604792-A | Agents for enhancing the immune response | BECTON DICKINSON CO (US) | 2005-04-06 | — | — | CN | claimed |
| US-20020016505-A1 | Heat storage material having solid/solid phase transition remains solid through application; heat resistance; materials handling | MERCK PATENT GMBH (DE) | 2002-02-07 | — | — | US | claimed |
| EP-1148108-A1 | Storage media for latent heat storage units | MERCK PATENT GmbH (DE) | 2001-10-24 | — | — | EP | claimed |
| US-6283336-B1 | Article for the delivery of foam products | THE PROCTER & GAMBLE COMPANY | 2001-09-04 | — | — | US | claimed |
| US-4698393-A | FRIEDEL CRAFTS CATALYSTS AND SUSPENSION POLYMERIZATION; MATERIALS HANDLING | RAYCHEM CORPORATION (US) | 1987-10-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | ALK, C9, MSR1 | SIGMAR1 449/4885TSHR 1094/4885ALDH1A1 1514/4885 |
| US-12178795-B2 | Method for treating metastatic prostate cancer | BPHL, KLK3, ACP3 | SIGMAR1 3322/4885TSHR 4032/4885ALDH1A1 572/4885 |
| US-12239626-B2 | Method for treating infectious diseases with isothiocyanate functional compounds | CFTR, TST, ICMT | SIGMAR1 1678/4885TSHR 1685/4885ALDH1A1 1558/4885 |
| US-12310939-B2 | Method for treating rheumatoid arthritis | MIF, TNF, MMP12 | SIGMAR1 1339/4885TSHR 1301/4885ALDH1A1 758/4885 |
| US-20020016505-A1 | Heat storage material having solid/solid phase transition remains solid through application; heat resistance; materials handling | HSPH1, HSP90AA1, HSPA1A | SIGMAR1 2815/4885TSHR 4373/4885ALDH1A1 1431/4885 |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | TST, TMSB10, NHERF1 | SIGMAR1 1720/4885TSHR 4015/4885ALDH1A1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.